skip to navigation

PMD Healthcare PMD Healthcare

Spiro PD 2.0 Wellness Management Services

Remote, real-time lung health
monitoring and management.

Implements easily to help achieve
performance measures, improve
outcomes, and control costs.

Disease Burden

Chronic Respiratory Illnesses are a real and growing problem for the US Healthcare System. 38 million patients suffer with either COPD or Asthma. COPD alone is the 3rd leading cause of death in the US. Direct economic impact of over $50 Billion annually in the US. 30% driven by ER Visits hospital admissions/readmissions.

  • 12.7 Million

    COPD Patients
  • 25.5 Million

    Asthma Patients
  • $53.7 Billion

    Total U.S. Costs (2008)
  • COPD 3rd Leading

    Cause of Death

Readmissions Point To The Chronic and Reoccurring Cycle For Patients:

Reoccurring Chart
  • The 30-day hospital readmission rate for COPD patients is approximately 25%
  • 41% of all hospital readmissions are COPD
  • Readmissions for COPD costs are 50% higher than the original admission
  • For the most severe patients, readmission length of stay (LOS) is twice as long (8 days) and results in 10 times higher mortality rates

A Real Issue That Needs Real Attention:

And healthcare stakeholders are taking action


ACO’s are first introduced to

  • Co-ordinate care
  • Improve Quality
  • Reduce Cost

Hospital Readmission Reduction Program Introduced to

  • Decrease 30 Day readmission rates
  • Reward top performers
  • Penalize excessive readmission rate

Value Modifier Program Introduced to

  • Incentivize providers on quality
  • Penalize poor performers
  • Initial program focused on groups of 100+ providers

Value Modifier Program Expands

  • Groups of 10+ are now included

Quality focused Programs continue to expand and evolve

  • Hospital readmission penalties exceed $428m
  • ACO’s have grown to 800+
  • Value Modifier Program covers all groups from solo+

Our Solution

PMD offers a Comprehensive Solution For All Stakeholders That is:

  • Clinically RelevantClinically Relevant
  • Easy to ImplementEasy to Implement
  • Financially SoundFinancially Sound

Simple as 1, 2, 3

Integrates a 1) proven breakthrough in personal spirometry,
2) HIPAA-compliant data portal, and 3) comprehensive wellness management services

  • Spiro PD 2.0 Collects Data: 1

    Spiro PD 2.0 Collects Data:

    Tri-Trend, medication management, biometric alerts

    Spiro PD, the first-ever personal spirometer, is highly interactive. It provides audio coaching to help patients perform the spirometry test completely and accurately. And it captures, wirelessly and in real time, data on compliance with each patient’s personal care plan plus critical Tri-Trend data.

  • Spiro PD 2.0 Delivers Data To PMD Portal: 2

    Spiro PD 2.0 Delivers Data To PMD Portal:

    HIPAA-compliant, patient-controlled

    Beyond archiving and offering access to data, the secure, HIPAA-compliant PMD Portal connects patients and their healthcare team to improve communications...and outcomes. Patients decide who gets their data for assessment of care needs in real time and revisions of care plans based on real-time evidence.

  • WMS Promotes Care Plan Compliance for Positive Outcomes: 3

    WMS Promotes Care Plan Compliance for Positive Outcomes:

    WMS delivers a critically important first: remote, real-time lung health monitoring and management that improve communication, increase care plan compliance, plus support the documentation and achievement of quality measures, all to improve patient outcomes.

    WMS monitors patient’s lung function and medication adherence, and provides alerts based upon the personalized care plan, as well as tracks and documents non face-to-face time spent by care team members reviewing patient data, care plans, and interventions. WMS disseminates data to HCPs, patients, and caregivers through portal alerts, email, or text messages.

Spiro PD 2.0 WMS Addresses The Most Critical
Pain Points For Providers:

  • Monitors

    Lung Function
    Medication Adherence
    Care Plan Compliance

  • Enhances Care Coordination

    HIPAA Compliant
    Personalized Care Plans
    Real Time Interventions

  • Reduces Readmissions

    Helps Prevent Exacerbation
    Reduced Costly ER Visits

  • Promotes Financial Benefits

    Helps Achieve Quality Measures
    Improves Outcomes
    Supports CCM Reimbursement

Evidence of Benefits

PMD Healthcare is well established and utilized among some of
the largest Health-Systems across the United States

U.S. Map Marked

Approved With A Large Global Presence

World Map

There is a growing body of evidence in support of what we do


Original Research Feasibility and Acute Care Utilization Outcomes of a Post-Acute Transitional Tele-monitoring Program (COPD/HF)


COPD and Heart Failure are chronic diseases that impart significant healthcare costs on the patient and health system.


The intervention was a prospective 90 day transitional care program following an acute event that integrated a mobile health technology and home visits for patients with COPD and/or Heart Failure.


The 30 day readmission rates were reduced by 50% for both COPD and Heart Failure patients versus the control group.

The program was feasible and satisfactory to patients with daily adherence greater than 70%.

Patients sustained clinically meaningful improvements 
in their health status.



Original Research Feasibility and Acute Care Utilization Outcomes of a Post-Acute Transitional Tele-monitoring Program (COPD/HF)



A pilot study of a mobile-phone-based home monitoring system to assist in remote interventions in cases of acute exacerbation of COPD


Patients with COPD often suffer from Acute Exacerbations (AECOPD), a sudden worsening of respiratory symptoms such as dyspnea and sputum. In the management of patients with COPD, timely intervention of AECOPD is important because exacerbations are responsible for gradual but irreversible progression of the disease and often require emergency department (ED) treatment. However, in practice patients with AECOPD often take the ‘‘wait and see’’ approach, and some of them fail to receive treatment, probably due to the unmet needs for health care.


We conducted a six-month feasibility study of a mobile-phone-based home monitoring system, called M-COPD. Patients with a history of moderate Acute Exacerbation of COPD (AECOPD) were given a mobile phone to record major symptoms (dyspnea, sputum color and volume), minor symptoms (cough and wheezing) and vital signs. A care team remotely monitored the recorded data and provided clinical interventions.


There were significantly lower hospital admissions with M-COPD, ED presentations and GP visits than in the matched period.

The results demonstrate the potential to analyze respiratory symptoms for early intervention of AECOPD.

Journal of Telemedicine and Telecare 2014, Vol. 20

COPD ED, Hospital and GP Visits


Journal of Telemedicine and Telecare 2014, Vol. 20

The Ability of Home Spirometry and Symptom Monitoring to Predict Exacerbations in Cystic Fibrosis


Patients (pts) with cystic fibrosis (CF) suffer frequent pulmonary exacerbations, diagnosed by decline in lung function and increased symptoms. Early and aggressive therapy is associated with better outcomes. 

CF pts do not usually monitor their lung function or symptoms at home, and exacerbations are only detected when pts are sick enough to seek care. The purpose of this study was to assess the feasibility of home monitoring.


This is a six month study of ten pts with CF. Each was given an electronic device to measure FEV1 twice daily and symptoms once daily. Data was transmitted to us weekly by phone, and exacerbations were scored using the Akron exacerbation scale. Medical records were examined for evidence of clinically detected exacerbations.


There were 28 exacerbations detected through home monitoring, but only 8 of these were clinically detected and reported by the pts to their physicians. Home monitoring detected exacerbations an average of 15.6 days before pts contacted the care center because of symptoms.

Although these are pilot study results, the data suggests home monitoring can detect exacerbations more than two weeks before patients typically seek medical care; therefore, early intervention may improve CF outcomes.

Excerpt From Pediatric 2014, Vol. 34, 532 “Poster Session Abstract” poster 376

The Ability of Home Spirometry and Symptom Monitoring to Predict Exacerbations in Cystic Fibrosis


Spirometry detected exacerbations an average of 16 days before patients began to feel symptoms.

…patients gained insight into their health through the use of home spirometry and were able to take steps to maintain their health through better medication adherence and better adherence with airway clearance techniques.


Pediatric Pulmonology 2009: 44(S32):343-44



Feasibility Of Home Spirometry Measurement In Children with Cystic Fibrosis


Medication adherence among children with CF is poor.  Poor adherence is associated with lower lung function studies, worse nutritional status and a greater frequency of exacerbations.

Survey data of 40 CF adolescents from our center show that 20% have doubts about the necessity of the treatment regimen & that nearly 80% are motivated by improvements in their lung function to stay adherent.

Offering children & adolescents with CF more frequent lung function monitoring could lead to improvements in treatment adherence, quality of life and health outcomes.


Five subjects, 10 –14 years of age, with CF were enrolled and three were randomly assigned a Spiro PD ® personal spirometer to measure their PFT once a week from home for 3 months.

Subjects were called once a week by the respiratory therapist to review PFT results.

The device also provided daily medication reminders for inhaled hypertonic saline, dornase alfa and CF multivitamins.


All subjects were able to successfully use the personal spirometer to measure their PFTs once a week from home.

Average training time was 30 minutes.

PFTs obtained on the personal spirometer correlated well with those obtained in clinic and with pulmonary symptoms.

Subjects appreciated the opportunity to review their PFT results during the weekly phone calls.

Participants stopped using the medication reminder feature due to alarms not being audible enough and finding it cumbersome to change alarm times to suit their changing schedules.

A Shakkottai M.D., A Nasrallah, SZ Nasr M.D., C.P.I.1 1Department of Pediatrics and Communicable Diseases, University of Michigan Medical

Feasibility Of Home Spirometry Measurement In Children with Cystic Fibrosis

Mean FEV1 and FEF25-75 %predicted at baseline and 
3-months in the intervention and control groups. The intervention group experienced a 3% increase in FEV1 and a 5% increase in FEF25-75. The control group had a 2% decline in FEV1 and a 15% decline in FEF25-75 % predicted.


A Shakkottai M.D., A Nasrallah, 
SZ Nasr M.D., C.P.I.1 
1Department of Pediatrics and Communicable 
Diseases, University of Michigan Medical

Contact us to learn more about Idiopathic Pulmonary Fibrosis.

Contact us to learn more about Asthma studies.

Cost Effectiveness

Spiro PD 2.0 and WMS Make Good Financial Sense!

For quality focused organizations and those in pay for performance and shared savings models,
Spiro PD 2.0 and WMS make solid financial sense.

Financial Flow Chart

Work with us to enhance care coordination, improve quality, reduce readmissions and improve outcomes.

Contact us today to receive a complimentary analysis specific to your organization demonstrating the clinical benefit, ease of implementation and financial benefits.